Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

BAKKALOĞLU EZGÜ S. A., Leventoglu E., Fakhouri F., Nester C. M.

NEW ENGLAND JOURNAL OF MEDICINE, vol.394, no.11, pp.1139-1140, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Letter
  • Volume: 394 Issue: 11
  • Publication Date: 2026
  • Doi Number: 10.1056/nejmc2600540
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Abstracts in Social Gerontology, BIOSIS, CINAHL, Educational research abstracts (ERA), EMBASE, Gender Studies Database, MLA - Modern Language Association Database, Public Affairs Index, Nature Index
  • Page Numbers: pp.1139-1140
  • Gazi University Affiliated: Yes

Abstract

To the Editor: The results of the VALIANT trial reported by Fakhouri et al. (Dec. 4 issue)1 provide compelling evidence that proximal C3 inhibition with pegcetacoplan can substantially reduce the degree of proteinuria and stabilize kidney function in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (MPGN). These results represent a major therapeutic advance for patients with disorders historically associated with poor renal prognosis and limited treatment options.2-5 Beyond its therapeutic implications, the trial reinforces the indispensable role of kidney biopsy in establishing a definitive diagnosis. In contemporary pediatric practice, genetic testing is increasingly being performed before biopsy; however, . . .